These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 15048960)
1. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Moriki T; Takahashi T; Ueta S; Mitani M; Ichien M Diagn Cytopathol; 2004 Apr; 30(4):251-6. PubMed ID: 15048960 [TBL] [Abstract][Full Text] [Related]
2. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528 [TBL] [Abstract][Full Text] [Related]
4. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976 [TBL] [Abstract][Full Text] [Related]
6. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662 [TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
8. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607 [TBL] [Abstract][Full Text] [Related]
9. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175 [TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen value as a marker in breast cancer. Narita D; Cimpean AM; Anghel A; Raica M Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473 [TBL] [Abstract][Full Text] [Related]
11. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? Fadare O; Wang SA; Hileeto D Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Nizzoli R; Bozzetti C; Naldi N; Guazzi A; Gabrielli M; Michiara M; Camisa R; Barilli A; Cocconi G Cancer; 2000 Feb; 90(1):61-6. PubMed ID: 10692218 [TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies. Vameşu S Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798 [TBL] [Abstract][Full Text] [Related]
14. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
15. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. Florena AM; Tripodo C; Guarnotta C; Ingrao S; Porcasi R; Martorana A; Lo Bosco G; Cabibi D; Franco V Pathobiology; 2007; 74(6):317-22. PubMed ID: 18087195 [TBL] [Abstract][Full Text] [Related]
16. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. Ferguson J; Chamberlain P; Cramer HM; Wu HH Diagn Cytopathol; 2013 Jul; 41(7):575-81. PubMed ID: 22807465 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489 [TBL] [Abstract][Full Text] [Related]
19. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
20. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Gong Y; Symmans WF; Krishnamurthy S; Patel S; Sneige N Cancer; 2004 Feb; 102(1):34-40. PubMed ID: 14968416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]